The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR(PDF, 524KB) and Technical Notes(PDF, 752KB) pages.


Download and Print: Download Printer-friendly PDF Download data


Table 4.26

Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Females by Race

Histologya All Races White Black Asian/
Pacific Islander
American Indian
/Alaska Nativeb
Hispanicc
Count Percent Count Percent Count Percent Count Percent Count Percent Count Percent
Adenocarcinomad 77,883 99.9% 58,870 99.9% 9,149 99.9% 8,401 99.9% 306 100.0% 8,297 99.9%
Adenocarcinoma in situ, NOS (8140/2) - - - - - - - - - - - -
Ductal carcinoma in situ e 66,284 85.0% 49,479 84.0% 8,046 87.9% 7,615 90.6% 270 88.2% 7,115 85.6%
Cribiform carcinoma in situ (8201/2) 7,009 9.0% 5,171 8.8% 863 9.4% 861 10.2% 18 5.9% 742 8.9%
Ductal carcinoma in situ, solid type(8230/2) 5,636 7.2% 4,353 7.4% 577 6.3% 615 7.3% 27 8.8% 508 6.1%
Ductal carcinoma in situ, NOS (8500/2) 20,775 26.6% 15,828 26.9% 2,441 26.7% 2,074 24.7% 104 34.0% 2,209 26.6%
Comedocarcinoma in situ (8501/2) 6,493 8.3% 4,846 8.2% 745 8.1% 798 9.5% 33 10.8% 678 8.2%
Ductal carcinoma in situ papillary(8503/2) 1,132 1.5% 762 1.3% 208 2.3% 139 1.7% - - 122 1.5%
Noninfiltrating intracystic carcinoma(8504/2) 255 0.3% 162 0.3% 42 0.5% 49 0.6% - - 28 0.3%
Ductal carcinoma in situ micropapillary(8507/2) 1,210 1.6% 926 1.6% 162 1.8% 102 1.2% - - 138 1.7%
Intraductal with other types of carcinoma in situ(8523/2) 23,587 30.3% 17,299 29.4% 2,997 32.7% 2,934 34.9% 82 26.8% 2,673 32.2%
Lobular carcinoma in situ (8520/2-8521/2, 8524/2) 9,076 11.6% 7,418 12.6% 812 8.9% 560 6.7% 32 10.5% 933 11.2%
Lobular carcinoma in situ, NOS (8520/2) 9,063 11.6% 7,410 12.6% 808 8.8% 560 6.7% 31 10.1% 932 11.2%
Lobular CISf with other CISf (8524/2) - - - - - - - - - - - -
Intraductal and lobular in situ carcinoma (8522/2) 2,016 2.6% 1,602 2.7% 228 2.5% 162 1.9% - - 195 2.3%
Other adenocarcinomasg 499 0.6% 367 0.6% 62 0.7% 61 0.7% - - 54 0.7%
Other in situ histologiesh 77 0.1% 59 0.1% - - - - - - - -
Total 77,960 100.0% 58,929 100.0% 9,155 100.0% 8,407 100.0% 306 100.0% 8,308 100.0%

Footnotes:

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Percents may not sum to 100 due to rounding.

a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

d Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

e Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

f CIS = Carcinoma in situ.

g Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

h Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.

Page Navigation: << Previous Next >>


The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.